Your browser doesn't support javascript.
loading
Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer.
Kim, Ji Won; Luck, Cuyler; Wu, Wei; Ponce, Rovingaile Kriska; Lin, Yone Kawe; Gupta, Nehal; Okimoto, Ross A.
Afiliação
  • Kim JW; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Jeju Research Institute of Pharmaceutical Sciences, College of Pharmacy, Jeju National University, Jeju, Republic of Korea.
  • Luck C; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Wu W; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Ponce RK; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Lin YK; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Gupta N; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
  • Okimoto RA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. Electronic address: ross.okimoto@ucsf.edu.
Cell Rep ; 41(1): 111443, 2022 10 04.
Article em En | MEDLINE | ID: mdl-36198276
ABSTRACT
Inactivation of Capicua (CIC) or upregulation of yes-associated protein 1, YAP1, leads to broad RAS-RAF-MEK-ERK inhibitor resistance and tumor progression in multiple human cancers. Despite these shared malignant phenotypes, it remains unclear whether CIC and YAP1 are mechanistically linked. Here, we show that the ERK-regulated transcription factor CIC can directly repress YAP1 expression through non-consensus GGAAGGAA DNA-binding motifs in a proximal YAP1 regulatory element. Through binding at GGAA repeats, CIC regulates YAP1 transcriptional output in both normal and human cancer cells. Silencing YAP1 in CIC-deficient cells restores MAPK inhibitor sensitivity and suppresses tumor growth. Thus, we uncover a molecular link between the MAPK-ERK effector CIC and YAP1 in human cells and established YAP inhibition as a strategy to target CIC-deficient cancers.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Repressoras / Neoplasias Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Repressoras / Neoplasias Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article